pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Lucentis · news · pharmadog
← back to Lucentis
News mentioning Lucentis
12
stories
4d
J&J bets $2.2B on Ollin’s vision loss drug
biopharma dive
4d
J&J pays $2.2B upfront for Ollin to challenge Roche’s Vabysmo with phase 3 bispecific
fiercebiotech
23d
Recon: FDA approves Stada’s Lucentis biosimilar; Lilly says ‘triple-G’ candidate bests Ozempic in diabetes
raps
Oct 12, 26
Merck reports mixed data for Lucentis competitor in diabetic macular edema
endpoints
Oct 12, 26
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
biopharma dive
Oct 12, 26
Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potential
fiercebiotech
Sep 28, 26
Kodiak skyrockets on positive study data for 2 eye drugs
biopharma dive
Sep 24, 26
Merck reveals study success, and possible safety worries, for eye drug hopeful
biopharma dive
Sep 24, 26
Merck’s experimental eye drug matches Roche’s VEGF inhibitor but safety concerns emerge
biospace
Sep 24, 26
Merck sees pivotal victory for $3B eye disease prospect
fiercebiotech
Aug 17, 26
EyePoint plummets on pivotal data for main drug
biopharma dive
Jul 22, 26
Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growth
biospace